Positive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation
/in Clinical Trial, Non-Metastatic, Phase 3/by MaxUPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Clinical Trial: JSB462 (Luxdegalutamide) in Combination With Abiraterone for mHSPC
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/in Clinical Trial, Metastatic, Phase 3/by MaxNewsletter 21/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! As you may have noticed, I have started writing about the research results that will be presented at ASCO 2025. And I still have many more to review and write about! I had to condense the information in this […]
Single-Cell RNA Sequencing Reveals Three Immune Archetypes in Bone Metastases Across Multiple Cancer Types
/in Immunotherapy, mRNA, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 1/2 Trial for MK-6070: A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers November 29, 2025
- UPDATE: Phase 1 GenSci143 Trial Set To Start By The End of December November 27, 2025
- Phase 2 Trial for The Combo Fasudil Hydrochloride Plus PD-1 Immune Checkpoint Blockade November 27, 2025
- Phase 1/2 Trial: Valemetostat Plus Darolutamide in mCRPC November 27, 2025